MedPath

Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

Phase 3
Completed
Conditions
Bilateral Nasolabial Fold Wrinkles
Interventions
Biological: Placebo
Biological: Autologous Human Fibroblast (azficel-T)
Registration Number
NCT00649428
Lead Sponsor
Castle Creek Biosciences, LLC.
Brief Summary

The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
203
Inclusion Criteria
  • Subject is at least 18 years of age
  • Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol
  • Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol
  • Ability to comply with the study requirements
  • Negative pregnancy test (Females)
  • Healthy post-auricular skin for biopsy
Exclusion Criteria
  • Excessive dermatochalasis of the treatment area
  • Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart
  • Total area to be treated exceeds 20 cm in length
  • Physical attributes which may prevent assessment or treatment as judged by the evaluator
  • Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study
  • Previous treatment with the sponsor's product
  • History of active autoimmune disease or organ transplantation
  • Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)
  • Active or chronic skin disease
  • Known genetic disorders affecting fibroblasts or collagen
  • Active systemic infection
  • Requires chronic antibiotic or steroidal therapy
  • Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study
  • Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects
  • Known allergic reactions to agents used in preparation of treatment
  • Excessive exposure to sun without adequate sun protection

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlPlacebo-
ActiveAutologous Human Fibroblast (azficel-T)-
Primary Outcome Measures
NameTimeMethod
Subject Wrinkle Assessment RespondersBaseline (prior to first treatment) and 6 months post final treatment

A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.

Evaluator Wrinkle Severity Assessment RespondersBaseline (prior to first treatment) and 6 months after last treatment

A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.

Secondary Outcome Measures
NameTimeMethod
Evaluator Wrinkle Severity Assessment RespondersBaseline (prior to first treatment) compared to 3rd treatment visit, 2 and 4 months post final treatment

A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.

Subject Wrinkle Assessment RespondersBaseline (prior to first treatment) compared to 3rd treatment visit, 2 and 4 months post final treatment

A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.

Trial Locations

Locations (7)

Silverburg Surgical & Medical Group

🇺🇸

Newport Beach, California, United States

Dermatology Research Institute, LLC

🇺🇸

Coral Gables, Florida, United States

Total Skin & Beauty Dermatology Center, PC

🇺🇸

Birmingham, Alabama, United States

River North Dermatology and Dermatologic Surgery

🇺🇸

Naperville, Illinois, United States

Dermatology, Laser & Vein Specialists of the Carolinas

🇺🇸

Charlotte, North Carolina, United States

Center for Skin Research

🇺🇸

Houston, Texas, United States

Aesthetic Solutions

🇺🇸

Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath